Visit the company at booth n ° 1129 in the exhibition hall

Elmsford, NY, December 08, 2021 (GLOBE NEWSWIRE) – NanoVibronix, Inc., (NASDAQ: NAOV), a healthcare device company that today produces UroShield® and PainShield® acoustic wave portable ultrasound therapy devices (SAW) has announced that it will be showcasing its PainShield products at the Workers’ Compensation Institute (WCI) 75th Annual Workplace Injury Training Conference December 12-15, 2021 at the Orlando World Center Marriott in Orlando , in Florida.

Brian Murphy, CEO of Nanovibronix, said, “The workers’ compensation market represents a huge opportunity for our pain management devices. We are a new entrant in this market with the recent signing of an agreement with a national provider of solutions to facilitate the reimbursement of our products. We look forward to engaging in discussions with other workers’ compensation payers at the conference to educate about the benefits and superiority of our PainShield products. Our goal within the Workers’ Compensation channel is to increase brand recognition and accelerate uptime.

PainShield is an ultrasound device that produces a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area, while maintaining the level of ultrasound energy at a safe and constant level. Its range of applications includes the resolution of acute and chronic pain through its many mechanisms of action. The product has wide applications for sports injuries. PainShield can be used by patients at home, at work, or in a clinical setting and can be used even while the patient is sleeping. Benefits for patients include ease of application and use, faster recovery time, high compliance, and increased safety and efficiency over existing devices that rely on higher frequency ultrasound.

About the Institute for Industrial Accidents

The Workers ‘Compensation Institute (WCI) is a nonprofit educational organization that serves as a comprehensive resource for all stakeholders in workers’ compensation. WCI sponsors the annual Workers ‘Compensation Educational Conference and brings together workers’ compensation professionals from across the country. This is the largest working conference in the country and the programming, networking, showroom and entertainment cannot be matched.

For more information on the conference, please visit:

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development activities in Nesher, Israel, focused on the development of medical devices using its patented technology of low intensity surface acoustic waves (SAW). The proprietary technology enables the creation of low frequency ultrasonic waves that can be used for a variety of medical applications, including disrupting biofilms and bacterial colonization, as well as relieving pain. The devices can be administered at home without the assistance of healthcare professionals. The company’s main products include PainShield® and UroShield®, which are portable devices suitable for home administration without the assistance of healthcare professionals. Additional information on NanoVibronix is ​​available at:

Forward-looking statements

This press release contains “forward-looking statements”. Such statements may be preceded by the words “intention”, “may”, “will”, “plans”, “expects”, “plans”, “projects”, “predicts”, “estimates”, “aims” , “Esteem”, “hopes”, “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company and cannot be predicted or quantified; therefore, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties associated with: (i) the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise capital to future if necessary, (ii) market acceptance of our existing and new products or long product delays in key markets; (iii) negative or unreliable clinical trial results; (iv) failure to obtain regulatory approvals for the sale of our products; (v) intense competition in the medical device industry from much larger multinational companies; (vi) product liability claims; (vii) product malfunctions; (viii) our limited manufacturing capacities and our recourse to the assistance of subcontractors; (ix) insufficient or inadequate refunds by government payers and / or other third parties for our products; (x) our ability to successfully obtain and maintain intellectual property protection covering our products; (xi) legislative or regulatory reform impacting the healthcare system in the United States or in foreign jurisdictions; (xii) our dependence on single-source suppliers for certain product components, (xiii) the need to raise additional capital to meet our future business requirements and obligations, as such capital may not be available, or may be expensive, dilutive, or difficult to obtain; (xiv) our business operations in foreign jurisdictions exposing us to additional challenges, such as exchange rate fluctuations, logistics and communication issues, the burden and cost of compliance with foreign laws and political instabilities and / or economic in specific jurisdictions; and (xv) the market and other conditions. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements are set out in the documents filed by the company with the Securities and Exchange Commission (SEC), including the company’s annual report on the form 10-K and its quarterly reports. on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at: The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise, except as required by law.

CONTACT: Brett Maas, Managing Principal Hayden IR, LLC 646-536-7331 [email protected]

Previous Scott Yenor: Protests took place in Boise State after the professor told a conference that men, not women, should be recruited into fields like medicine and law
Next # 10 becomes # 1 Christmas party spot in these 21 memes